Replies to post #559773 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Thanks for the reply. Like I said, I cannot make heads or tails of any of the comments that you post. I am focused on the living murcidencel patients and the combo study and the platform potential beyond GBM/rGBM.

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847








https://ceoworld.biz/2022/04/05/top-5-medical-journals-in-the-world-everyone-should-know-about/

https://clinicaltrials.gov/ct2/show/NCT04201873

Murcidencel (DCVax-L) is discussed beginning at minute 40, to focus on Keytruda (pembrolizumab) plus DCVax in combo at UCLA, skip to minute 45:40

https://cancer.ucla.edu/research/ucla-brain-spore/research-projects

https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/

https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter